

IBT's results for the first quarter of 2016

The Extraordinary General Meeting of BioGaia on 18 March resolved to distribute the shares in the subsidiary Infant Bacterial Therapeutics AB (IBT) to BioGaia's shareholders. On 29 March 2016, trading of IBT's class B shares commenced on Nasdaq First North. IBT's results up to March 29 will be consolidated in BioGaia's financial statements.

IBT has today announced a rights issue. The prospectus that IBT will make public in relation to the rights issue will include IBT's results for the first quarter of 2016. The loss for the period was SEK -5.2 million, compared to SEK -3.7 million corresponding period of last year, and is included in BioGaia's profit for the first quarter. Because BioGaia will not publish its interim report until 10 May, BioGaia is also publishing IBT's results for the first quarter today.

For additional information

Axel Sjöblad, Managing Director: +46 8 555 293 00
Margareta Hagman, Executive Vice President +46 8-555 293 00

Latest press releases from BioGaia

2016-04-25 BioGaia's oral health probiotics to be launched in Hong Kong
2016-04-06 Notice to attend the Annual General Meeting of BioGaia AB (publ)
2016-03-18 Extraordinary General Meeting of BioGaia AB

BioGaia has published this information in accordance with the Swedish Securities Act. The information was issued for publication on 27 April 2016 08:15 am CET.

BioGaia is a healthcare company that develops, markets and sells probiotic products with documented health benefits. The products are primarily based on the lactic acid bacterium *Lactobacillus reuteri* which has probiotic, health-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap list of the Nasdaq OMX Nordic Exchange Stockholm. www.biogaia.com

**BioGaia AB Box 3242. SE-103 64 STOCKHOLM Street address: Kungsbrogatan 3A, Stockholm
Telephone: +46 8 555 293 00, Corp. identity no. 556380-8723 www.biogaia.com.**